Stryker Corporation Q3 FY2026 results
$309.64−0.88%
Stryker Corporation reported revenue of $6.52 billion, up 7.6% from a year earlier, net income of $753 million and diluted earnings per share of $1.96 against $2.22 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).
From its quarterly report, the results first announced on 29 Oct 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $6.52B | $6.06B | +7.6% |
| Gross profit | $4.25B | $3.85B | +10.3% |
| Gross margin | 65.2% | 63.6% | +1.6 pts |
| Operating income | $1.03B | $1.14B | −8.9% |
| Operating margin | 15.9% | 18.7% | −2.9 pts |
| Net income | $753.0M | $859.0M | −12.3% |
| Diluted EPS | $1.96 | $2.22 | −11.7% |
| Operating cash flow | $1.46B | $1.54B | −5.1% |
| Capital expenditure | $237.0M | $187.0M | +26.7% |
| Free cash flow | $1.22B | $1.35B | −9.5% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| Organic net sales (change on a year) | 7.7% | down 1.8 points |
| Neuro Cranial Instruments revenue | $670.0M | up 5.2% |
| Orthopaedic Instruments revenue | $535.0M | up 8.7% |
| Enabling Technologies revenue | $28.0M | down 37.8% |
| Medical revenue | $1.1B | up 9.7% |
| Endoscopy revenue | $1.0B | up 14.0% |
| Trauma and Extremities revenue | $1.0B | up 5.2% |
| Instruments revenue | $996.0M | up 5.0% |
| Ortho Tech revenue | $754.0M | up 15.8% |
| Knees revenue | $635.0M | up 1.1% |
| Vascular revenue | $566.0M | up 7.8% |
| Hips revenue | $453.0M | down 0.9% |
| Spinal Implants revenue | $4.0M | down 33.3% |
| MedSurg and Neurotechnology (revenue) | $3.7B | up 9.2% |
| Orthopaedics (revenue) | $2.9B | up 5.7% |
| United States revenue | $5.0B | up 8.3% |
| International revenue | $1.6B | up 5.7% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $6.52B | +7.6% | $1.96 |
| Q2 FY2026 | 30 Jun 2026 | $6.59B | +9.4% | $3.30 |
| Q1 FY2026 | 31 Mar 2026 | $6.02B | +2.6% | $1.93 |
| Q4 FY2025 | 31 Dec 2025 | $7.17B | +11.4% | $2.20 |
| Q3 FY2025 | 30 Sep 2025 | $6.06B | +10.2% | $2.22 |
| Q2 FY2025 | 30 Jun 2025 | $6.02B | +11.1% | $2.29 |
| Q1 FY2025 | 31 Mar 2025 | $5.87B | +11.9% | $1.69 |
| Q4 FY2024 | 31 Dec 2024 | $6.44B | +10.7% | $1.41 |
More on Stryker Corporation: financial statements · revenue · earnings per share
SYK's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.
